APA (7th ed.) Citation

Fahmy, O., Ahmed, O. A. A., Khairul-Asri, M. G., Alhakamy, N. A., Alharbi, W. S., Fahmy, U. A., . . . Caraci, F. (2022). Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: A systematic review and meta-analysis. Multidisciplinary Digital Publishing Institute.

Chicago Style (17th ed.) Citation

Fahmy, Omar, et al. Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab Versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-analysis. Multidisciplinary Digital Publishing Institute, 2022.

MLA (9th ed.) Citation

Fahmy, Omar, et al. Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab Versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-analysis. Multidisciplinary Digital Publishing Institute, 2022.